Create a free account to see ACCE Scores
Sign up for free to unlock scores, score breakdowns, and stock analysis.
$48.43
+9.03%today
MKT CAP
$12.3B
+5.9% · 1Y
Earnings History
+16.2%
+16.2%
+16.2%
+14.0%
Q2 '25
Q3 '25
Q4 '25
Q1 '26
Analyst Targets
Current price
$48.43
Low
$35.00
Analyst Mean
$48.06
High
$60.00
17 analystsBuy
Full Financials
Trailing P/E15.3x
Forward P/E11.5x
EV/EBITDA-
Price/Sales-
Dividend Yield-
Revenue Growth YoY-
Earnings Growth YoY-
Revenue Growth QoQ+2.0%
5y Revenue CAGR+12.9%
5y Earnings CAGR+62.5%
Gross Margin-
Operating Margin-
Net Margin-
ROE-
Debt / Equity-
Free Cash Flow-
Insider Ownership2.0%
Institutional Ownership106.5%
Short % of Float15.10%
Days to Cover11.9d
1 Week-1.3%
1 Month-
3 Months-
6 Months-
YTD-
1 Year-
3 Years-
5 Years-
vs 50-day SMA-
vs 200-day SMA-
vs 52w High-
vs 52w Low-
Insider Transactions
| Filer | Role | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| MORRISSEY MICHAEL M | Chief Executive Officer | Stock | 160,437 | $0.00 | $0.00M | 2026-02-26 |
| SENNER CHRISTOPHER J. | Chief Financial Officer | Stock | 52,018 | $0.00 | $0.00M | 2026-02-26 |
| HALEY PATRICK JOSEPH | Officer | Stock | 40,459 | $0.00 | $0.00M | 2026-02-26 |
| AFTAB T DANA | Officer | Stock | 52,018 | $0.00 | $0.00M | 2026-02-26 |
| HEFTI BRENDA | General Counsel | Stock | 23,119 | $0.00 | $0.00M | 2026-02-26 |
Top Holders
| Holder | Type | % Held | Value | Δ Shares | As of |
|---|---|---|---|---|---|
| Blackrock Inc. | institution | 11.89% | $1.47B | +2.84% | 2025-12-31 |
| Vanguard Group Inc | institution | 10.04% | $1.24B | -2.20% | 2025-12-31 |
| Farallon Capital Management LLC | institution | 6.18% | $0.76B | -19.44% | 2025-12-31 |
| Renaissance Technologies, LLC | institution | 5.48% | $0.68B | -10.00% | 2025-12-31 |
| AQR Capital Management, LLC | institution | 5.38% | $0.66B | +48.76% | 2025-12-31 |
| State Street Corporation | institution | 4.13% | $0.51B | -5.61% | 2025-12-31 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | fund | 3.39% | $0.42B | -0.56% | 2026-03-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | fund | 3.17% | $0.39B | +0.18% | 2025-12-31 |
| Fuller & Thaler Asset Management Inc. | institution | 3.13% | $0.39B | -4.33% | 2025-12-31 |
| LSV Asset Management | institution | 3.05% | $0.38B | -0.29% | 2025-12-31 |
| Geode Capital Management, LLC | institution | 2.96% | $0.37B | -1.85% | 2025-12-31 |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund | fund | 2.67% | $0.33B | -6.93% | 2025-12-31 |
| Invesco Ltd. | institution | 2.38% | $0.29B | +1.58% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | fund | 2.28% | $0.28B | -4.65% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | fund | 1.28% | $0.16B | -3.88% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | fund | 1.14% | $0.14B | +0.33% | 2025-12-31 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P MidCap Quality ETF | fund | 0.99% | $0.12B | -1.22% | 2026-03-31 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | fund | 0.84% | $0.10B | -10.47% | 2026-03-31 |
| SPDR S&P MIDCAP 400 ETF TRT-State Street SPDR S&P Mid Cap 400 ETF TRT | fund | 0.77% | $0.09B | -0.42% | 2026-03-31 |
| iShares Trust-iShares Biotechnology ETF | fund | 0.74% | $0.09B | -3.47% | 2026-03-31 |
| Ticker | Cap | Score | P/E | Fwd P/E | EV/EBITDA | ROE | Gross | D/E | Div |
|---|---|---|---|---|---|---|---|---|---|
| MDGL | $12.4B | 20 | - | 42.3 | - | - | - | - | 0.00% |
| IONS | $12.7B | 41 | - | - | - | -67.6% | 11% | 531.05 | 0.00% |
| AXSM | $11.4B | 49 | - | 37.4 | - | -349.4% | 93% | 402.84 | 0.00% |
| BBIO | $13.4B | 52 | - | 128.7 | - | - | 96% | - | 0.00% |
| SMMT | $13.8B | 5 | - | - | - | - | - | - | 0.00% |
| ARWR | $11.0B | 12 | 49.5 | - | - | - | - | - | 0.00% |
Peers selected by sector + industry + nearest market cap. Best in column highlighted green, worst red.
Unlock Full Financials
Growth metrics, valuation multiples, and profitability ratios on Starter+.
Recent Alerts
No alerts yet for EXEL.
Want deep analysis?
This stock isn't in the ACCE researched universe. Browse 300+ stocks with full thesis, scores, and financial models.
Browse ACCE Indices →Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.